Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 69% of modeled bridge. Strengths: Commercial Payer %, Occupancy Rate. Risks: Revenue per Bed. Risk-adjusted uplift: $0.3M (vs $0.4M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $138K | $8K | $147K | $0 | 12mo |
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $144K | $144K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $22K | $65K | $88K | $276K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 53.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | $0 | $37K | $73K | $110K | $147K | $147K | $147K | $147K |
| Cost to Collect | $0 | $36K | $72K | $108K | $144K | $144K | $144K | $144K |
| A/R Days Reduction | $0 | $29K | $58K | $88K | $88K | $88K | $88K | $88K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $107K | $213K | $315K | $388K | $388K | $388K | $388K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $388K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 87% / 22.9x | 92% / 25.8x | 96% / 28.7x | 98% / 30.2x | 100% / 31.6x |
| 9.0x | 82% / 20.0x | 87% / 22.6x | 91% / 25.2x | 93% / 26.5x | 94% / 27.8x |
| 10.0x | 78% / 17.7x | 82% / 20.0x | 86% / 22.3x | 88% / 23.5x | 90% / 24.7x |
| 11.0x | 74% / 15.8x | 78% / 17.9x | 82% / 20.0x | 84% / 21.1x | 86% / 22.1x |
| 12.0x | 70% / 14.2x | 74% / 16.1x | 78% / 18.1x | 80% / 19.0x | 82% / 20.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 62% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.5x, adding 6.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $160K | — | $160K | 2.2% |
| Year 1 | $165K | +$258K | $423K | 5.9% |
| Year 2 | $170K | +$388K | $558K | 7.8% |
| Year 3 | $175K | +$388K | $563K | 7.8% |
| Year 4 | $180K | +$388K | $568K | 7.9% |
| Year 5 | $186K | +$388K | $573K | 8.0% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Denial Rate Reductio | $73K | $110K | $147K | $176K |
| Cost to Collect | $72K | $108K | $144K | $173K |
| A/R Days Reduction | $44K | $66K | $88K | $105K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $194K | $291K | $388K | $465K |
Peer Context — Where This Hospital Sits
Key metrics vs 120 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.2% | -22.5% | -5.0% | 4.3% | P64 |
| Net-to-Gross | 35.8% | 29.4% | 39.6% | 53.0% | P38 |
| Occupancy | 58.6% | 21.7% | 45.7% | 64.3% | P65 |
| Rev/Bed | $171K | $270K | $459K | $885K | P5 |
| Exp/Bed | $167K | $265K | $468K | $983K | P8 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.